Turunen Andrew M, Coombs Reilly A, Garg Sushil Kumar
School of Medicine, Medical College of Wisconsin-Central Wisconsin, Wausau, WI.
Division of Gastroenterology, Mayo Clinic Health System, Eau Claire, WI.
ACG Case Rep J. 2024 Dec 27;12(1):e01579. doi: 10.14309/crj.0000000000001579. eCollection 2025 Jan.
Semaglutide, a glucagon-like peptide-1 receptor agonist, used for Type 2 diabetes mellitus and more recently for weight loss, often causes gastrointestinal adverse effects such as delayed gastric emptying and abdominal discomfort. Current literature has not described an associated case of gastric pneumatosis with semaglutide use. We report a 61-year-old man on semaglutide for 9 months with gastric pneumatosis. Symptoms resolved on discontinuation. Clinicians should be vigilant for significant gastrointestinal adverse effects, including pneumatosis with semaglutide use.
司美格鲁肽是一种胰高血糖素样肽-1受体激动剂，用于治疗2型糖尿病，最近也用于减肥，它常引起胃肠道不良反应，如胃排空延迟和腹部不适。目前的文献尚未描述使用司美格鲁肽相关的胃壁积气病例。我们报告一名61岁男性，使用司美格鲁肽9个月后出现胃壁积气。停药后症状缓解。临床医生应警惕严重的胃肠道不良反应，包括使用司美格鲁肽时出现的胃壁积气。
